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Abstract
Background  and  objectives:  The  use  of  tranexamic  acid  in  primary  total  knee  replacement  sur-
geries has  been  the  subject  of  constant  study.  The  strategies  to  reduce  bleeding  are  aimed  at
reducing  the  need  for  blood  transfusion  due  to  the  risks  involved.  In  this  study  we  evaluated
the use  of  tranexamic  acid  in  reducing  bleeding,  need  for  blood  transfusion,  and  prevalence  of
postoperative  deep  vein  thrombosis  in  primary  total  knee  replacement.
Method:  62  patients  undergoing  primary  total  knee  replacement  were  enrolled  in  the  study,
from June  2012  to  May  2013,  and  randomized  to  receive  a  single  dose  of  2.5  g  of  intravenous
tranexamic  acid  (Group  TA)  or  saline  (Group  GP),  5  min  before  opening  the  pneumatic  tourni-
quet, respectively.  Hemoglobin,  hematocrit,  and  blood  loss  were  recorded  24  h  after  surgery.
Deep vein  thrombosis  was  investigated  during  patient’s  hospitalization  and  15  and  30  days  after
surgery in  review  visits.
Results:  There  was  no  demographic  difference  between  groups.  Group  TA  had  13.89%  decreased
hematocrit (p  =  0.925)  compared  to  placebo.  Group  TA  had  a  decrease  of  12.28%  (p  =  0.898)  in
hemoglobin  compared  to  Group  GP.  Group  TA  had  a  mean  decrease  of  187.35  mL  in  blood  loss
(25.32%) compared  to  group  GP  (p  =  0.027).  The  number  of  blood  transfusions  was  higher  in
Group GP  (p  =  0.078).  Thromboembolic  events  were  not  seen  in  this  study.∗ Corresponding author.
E-mail: danielvolquind@gmail.com (D. Volquind).
ttp://dx.doi.org/10.1016/j.bjane.2014.11.004
104-0014/© 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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Conclusion:  Tranexamic  acid  reduced  postoperative  bleeding  without  promoting  thromboem-
bolic events.
©  2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Uso  do  ácido  tranexâmico  em  artroplastia  total  primária  de  joelho:  repercussões  na
perda  sanguínea  perioperatória
Resumo
Justiﬁcativa  e  objetivos:  O  uso  do  ácido  tranexâmico,  em  cirurgias  de  artroplastia  total
primária de  joelho,  tem  sido  objeto  de  constante  estudo.  As  estratégias  para  reduc¸ão  de
sangramento  visam  à  reduc¸ão  da  necessidade  de  transfusão  de  sangue  devido  aos  riscos  que
apresentam.  Neste  estudo,  propomos  a  avaliac¸ão  do  uso  do  ácido  tranexâmico  na  reduc¸ão  do
sangramento,  na  necessidade  de  transfusão  de  sangue  e  na  prevalência  de  trombose  venosa
profunda  (TVP)  pós-operatória  em  artroplastia  total  primária  de  joelho.
Método:  Foram  estudados  62  pacientes  submetidos  à  artroplastia  primária  total  de
joelho, de  junho  de  2012  a  maio  de  2013,  randomizados  para  receber  ácido  tranexâmico
2,5 g  endovenoso  (grupo  AT),  em  dose  única,  ou  soro  ﬁsiológico  (grupo  GP),  cinco  minutos  antes
da abertura  do  torniquete  pneumático,  respectivamente.  Foram  feitas  dosagens  de  hemoglobina
e hematócrito  e  medida  a  perda  sanguínea  24  horas  após  a  cirurgia.  A  TVP  foi  pesquisada
durante a  internac¸ão  do  paciente,  15  e  30  dias  após  a  cirurgia  nas  consultas  de  revisão.
Resultados:  Não  houve  diferenc¸as  demográﬁcas  entre  os  grupos  estudados.  O  grupo  GT  apre-
sentou queda  do  hematócrito  13,89%  (p  =  0,925)  comparado  com  o  grupo  placebo.  O  grupo
GT apresentou  diminuic¸ão  de  12,28%  (p  =  0,898)  da  hemoglobina  comparado  com  o  grupo  GP.
O grupo  GT  apresentou  uma  diminuic¸ão  média  de  187,35  ml  nas  perdas  sanguíneas  (25,32%)
quando comparado  com  o  grupo  GP  (p  =  0,027).  O  número  de  transfusões  sanguíneas  foi  maior
no grupo  GP  (p  =  0,078).  Eventos  tromboembólicos  não  foram  evidenciados  neste  estudo.
Conclusões:  O  ácido  tranexâmico  diminuiu  o  sangramento  pós-operatório  sem  promover  eventos
tromboembólicos.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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The  proposal  to  use  tranexamic  acid  as  a  strategy  to  reduce
blood  loss  in  surgery  of  primary  total  knee  replacement  has
been  the  subject  of  constant  study,  because  it  is  a  proce-
dure  associated  with  signiﬁcant  amounts  of  bleeding  that
can  reach  20%  of  the  volume  in  patients  with  signiﬁcant
comorbidities  related  to  cardiovascular,  cerebrovascular,
and  metabolic  systems,  due  to  the  epidemiological  charac-
teristics  of  knee  osteoarthritis/arthrosis.1
In  these  patients,  blood  loss  leading  to  a  perioperative
anemia  promotes  high  morbidity  and  mortality.2 Patients
with  perioperative  anemia  have  a  longer  hospital  stay  asso-
ciated  with  a  greater  need  for  the  use  of  resources,  including
blood  transfusions,  blood  products,  and  admission  to  the
intensive  care  unit.3--5
Strategies  for  reducing  bleeding  have  been  used  to
reduce  the  need  for  transfusion  of  blood  and  its  products  due
4to  the  associated  risks. Not  only  the  transmission  of  viral
and  bacterial  diseases,  but  the  immunomodulation  related
to  homologous  transfusion  has  been  a  growing  concern,
especially  as  we  evidence  an  increase  in  the  prevalence  of
E
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drostheses  infections,  immunosuppression,  and  the  already
een  relationship  of  neoplasms  arising  in  patients  receiving
his  type  of  transfusion.4,6--8
In  this  study,  we  propose  to  evaluate  the  use  of  tranex-
mic  acid  in  reducing  bleeding,  need  for  transfusion  of  blood
nd  blood  products,  and  prevalence  of  postoperative  deep
enous  thrombosis  in  primary  total  knee  replacement.
ethods
fter  approval  by  the  local  Research  Ethics  Committee  and
btaining  written  informed  consent,  62  patients  undergo-
ng  primary  total  knee  replacement  due  to  osteoarthrosis  or
heumatoid  arthritis,  from  June  2012  to  May  2013,  were  ran-
omized  to  receive  intravenous  tranexamic  acid  2.5  g  (Group
A)  as  a  single  dose  or  saline  solution  (Group  P)  5  min  before
he  opening  of  the  pneumatic  tourniquet,  respectively.
xclusion  criteria  were  patient’s  refusal  to  participate  in  the
tudy,  allergies  to  drugs  used,  changes  related  to  coagula-
ion,  use  of  nonsteroidal  anti-inﬂammatory  or  antiplatelet
rugs  seven  days  before  surgery,  kidney  or  liver  failure,
2 D.  Volquind  et  al.
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regnancy,  and  previous  history  of  deep  venous  thrombosis
r  pulmonary  embolism.
Randomization  was  performed  using  a  software:  the
ttp://www.randomizer.org by  the  hospital  pharmacist,  not
articipating  in  the  study  and  conﬁdentially.  To  each  patient
f  both  groups,  a  0.9%  saline  100  mL  was  given  without  iden-
iﬁcation,  with  tranexamic  acid  or  saline  solution.  All  study
articipants  were  blind  to  what  was  inside  the  saline  solu-
ion  offered  by  the  hospital  pharmacy.  Anesthetic  technique
as  freely  chosen  by  the  anesthesiologists  to  be  applied  to
tudy  participants,  as  well  as  the  surgical  technique.  Total
nee  replacement  was  performed  with  cemented  prosthe-
is  using  pneumatic  tourniquet  inﬂated  with  compressed  air
ith  pressure  of  150  mmHg  above  the  systolic  blood  pressure
f  the  patient.  All  patients  received  prophylaxis  for  deep
enous  thrombosis  with  unfractionated  heparin  at  5000  UI
ubcutaneously  every  8  h  after  the  ﬁrst  dose  applied  before
neumatic  tourniquet  inﬂation  and  used  compression  stock-
ngs  on  both  legs  during  the  seven  days  following  surgery.
Postoperative  blood  loss  was  measured  in  drainage  sys-
em  installed  by  the  surgeon  in  the  surgical  wound  and
ecorded  in  the  ﬁrst  24  h  after  surgery.  Hematocrit  and
emoglobin  values  were  measured  24  h  after  surgery.  The
eed  for  blood  transfusion  was  observed  in  both  groups
t  24  h  following  surgery.  The  criteria  for  transfusion  were
stablished  according  to  the  protocol  used  by  the  surgeon:
leeding  greater  than  20%  of  blood  volume  or  postoperative
emoglobin  less  than  8  g  dL−1.
Postoperative  deep  vein  thrombosis  (DVT)  was  inves-
igated  through  clinical  history  and  physical  examination
uring  the  patient’s  hospital  stay,  and  Doppler  ultrasound
erformed  with  ﬂow  analysis  in  the  region  with  clinically
uspected  DVT.  In  the  follow-up  visit,  15  and  30  days  after
urgery,  the  systematic  investigation  was  repeated  by  the
urgeon.
Statistical  analysis  was  performed  with  SPSS  software
ersion  22.0.  Data  were  analyzed  with  the  Student’s  t-test
or  quantitative  variables  and  chi-square  test  for  qualitative
ariables.
esults
ata  from  62  patients  were  analyzed,  30  patients  in  placebo
roup  (Group  P)  and  32  in  tranexamic  acid  group  (Group
A),  where  30.64%  (n  =  19)  of  the  patients  were  male  and
9.35%  (n  =  43)  female.  There  were  no  demographic  differ-
nces  between  the  two  groups  (Table  1).
Table  1  Demographic  data.
Group  placebo
n =  30
Group  TA
n =  32
p
Age  (years)  63.96  ±  4  67.87  ±  5  0.180
Sex
Male 9  10
Female  21  22
Weight  (kg)  82.96  ±  3  83.46  ±  11  0.729
ASA
I/II 3/27  0/22  0.212
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bigure  1  Graph  showing  the  difference  in  bleeding  volume
mL) in  24  h  between  groups  (p  =  0.027).
The  mean  initial  hematocrit  (Hti)  was  40.03  ±  0.006%  in
roup  TA  and  the  mean  ﬁnal  hematocrit  (Htf)  was  31.19  ±
.017%,  demonstrating  a  hematocrit  reduction  of  22.08%.  In
roup  P,  Hti  was  42.08  ±  0.024%  and  Htf  31.27  ±  0.010%,  pre-
enting  a  hematocrit  reduction  of  25.64%.  Group  TA  showed
 hematocrit  fall  of  13.89%  (p  =  0.925)  compared  to  placebo
roup.
Mean  initial  hemoglobin  (Hbi)  in  group  TA  was  13.36  ±
.05  g  dL−1.  The  mean  hemoglobin  after  the  procedure
Hbf)  was  10.52  ±  1.342  g  dL−1, showing  a  decrease  in  Hb
f  21.26%  in  this  group  after  surgery.  In  group  P,  Hbi  was
3.96  ±  1  g  dL−1 and  Hbf  was  10.57  ±  0.95  g  dL−1,  showing  a
ecrease  in  Hb  of  24.29%.  The  group  TA  showed  a  decrease
n  Hb  of  12.28%  (p  =  0.898)  compared  to  group  P.
The  mean  postoperative  bleeding  in  group  TA  was
52.81  ±  107  mL  and  in  group  P  it  was  740.16  ±  205  mL.
roup  TA  showed  a  mean  decrease  of  blood  loss  of  187.35  mL
25.32%)  compared  to  group  P  (p  = 0.027)  (Fig.  1).
Group  P  needed  the  double  packed  red  blood  cells  (RBC)
nits  transfused  (8)  compared  to  group  TA  (4)  (p  =  0.078).
Deep  venous  thrombosis  was  not  observed  in  both  groups.
iscussion
he  present  study  showed  a  reduction  in  postoperative
leeding  in  patients  who  received  tranexamic  acid  because
ntiﬁbrinolytic  drugs  promote  reduction  of  ﬁbrinolysis.  Sur-
ical  trauma  releases  the  tissue  plasminogen  activator  (t-PA)
nd  the  ﬁbrinolytic  system  is  activated.  The  t-PA  is  the  main
nzyme  responsible  for  plasminogen  conversion  to  plasmin.
hrombin  also  activates  ﬁbrinolysis  by  vascular  endothelium
-PA  release.9 Surgical  stress  increases  plasmin  release  at  the
ite  of  vascular  damage  and  ampliﬁes  ﬁbrinolysis.
Tranexamic  acid  (trans-4-(aminomethyl)cyclohexane
arboxylic  acid),  which  is  a  synthetic  ﬁbrinolysis  inhibitor,
cts  through  competitive  inhibition  of  plasminogen  activa-
ion  in  plasmin,10,11 which  results  in  a  ﬁbrinolysis  delay  due
o  non-plasmin  formation,  binding  to  ﬁbrinogen  or  to  ﬁbrin
onomers  does  not  occur  and  results  in  a  clot  stabilization.4
he  choice  of  drugs  for  the  study  was  based  on  the  safety
roﬁle  and  its  efﬁcacy  reported  in  the  literature.
Among  the  strategies  to  reduce  perioperative  bleeding  in
nee  replacement  there  is  the  use  of  pneumatic  tourniquet
uring  the  perioperative  period.12 However,  this  tourniquet
ecreases  intraoperative  blood  loss,  but  when  deﬂated  an
ncrease  in  bleeding  is  seen,  which  is  explained  by  the  hyper-
brinolysis  due  to  plasmin  release  from  the  surgical  bed.13,14
Several  authors  studied  tranexamic  acid  to  establish  its
ffect  in  reducing  bleeding  and  need  for  transfusion  of
lood  and  blood  products  in  primary  total  knee  replacement.
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1Use  of  tranexamic  acid  in  primary  total  knee  replacement  
However,  there  was  no  consensus  regarding  dose  and  time
to  administer  the  drug  under  study.15--17
Orpen  et  al.  reported  a  signiﬁcant  blood  loss  reduction  of
43.5%  (p  =  0.006)  in  the  immediate  postoperative  period  in
the  group  receiving  15  mg  kg−1 intravenous  tranexamic  acid
at  the  time  of  cemented  knee  prosthesis  placement  com-
pared  to  the  group  receiving  saline  solution  at  the  same
time.  There  were  no  reports  of  deep  vein  thrombosis  in  both
groups.12
In  a  study  of  patients  with  hip  fracture,  the  intravenous
administration  of  tranexamic  acid  (15  mg  kg−1)  at  the  time
of  skin  incision  and  repeated  3  h  later  (total  of  30  mg  kg−1)
reduced  the  need  for  blood  transfusion.18
Studying  the  efﬁcacy  of  antiﬁbrinolytic,  Camarasa  used
intravenous  tranexamic  acid  at  a  dose  of  10  mg  kg−1 before
deﬂating  the  pneumatic  tourniquet,  and  repeated  it  3  h
after  the  same  intravenous  dose  and  demonstrated  a
decreased  blood  loss  in  patients  undergoing  total  knee
replacement.19
Recent  systematic  review  of  randomized  controlled  tri-
als  concluded  that  the  use  of  tranexamic  acid  as  a  bleeding
reduction  strategy  reduced  the  need  for  blood  transfusions
by  at  least  50%  and  its  complications,  indicating  that  this
drug  reduces  blood  loss  in  at  least  300  mL----such  ﬁndings  are
similar  to  that  found  by  the  authors.20
In  this  study,  we  use  tranexamic  acid  in  equal  dose  (2.5  g)
for  all  patients,  which  resulted  in  a  mean  of  30  mg  kg−1
applied  5  min  before  opening  the  pneumatic  tourniquet  in
rapid  infusion.  A  study  of  bleeding  reduction  in  surgeries  in
which  there  is  ﬁbrinolysis  activation  advocated  the  use  of
tranexamic  acid  doses  between  2  and  7  g.21
Regarding  hematocrit  and  hemoglobin  levels  in  this  study,
although  there  was  a  greater  decrease  in  Hb  in  group  TA,  it
was  not  enough  to  require  blood  transfusion  according  to
the  protocol  adopted  by  the  surgeon.  In  the  surgical  pro-
tocol,  patients  who  presented  Hb  <8  g  dL−1 or  postoperative
blood  loss  >20%  of  blood  volume  would  be  submitted  to  blood
transfusion.
This  approach  is  consistent  with  the  literature  with
regard  to  lower  the  patient’s  exposure  to  homologous  blood
transfusion.  By  using  a  simple  protocol,  similar  to  that  pro-
posed  by  the  surgeon  in  the  present  study,  Ballantyne  et  al.
showed  a  31%  reduction  in  blood  transfusions  when  adopted
as  a  transfusion  criterion  a  Hb  of  8.5  g  dL−1 compared  to  Hb
of  11  g  dL−1.22
With  the  same  purpose,  Zadzilka  et  al.  recommended  as
a  strategy  to  reduce  preoperative  transfusion  of  blood  and
blood  products  the  establishment  of  a  tolerable  Hb  level  in
order  to  perform  the  transfusion.23
In  this  study,  the  need  for  units  of  blood  transfused  was
double  in  group  P.  However,  we  cannot  claim  a  relation-
ship  with  or  without  the  use  of  tranexamic  acid  because  the
result  was  not  statistically  signiﬁcant.
Studies  have  reported  the  possibility  of  increased  throm-
boembolic  events  related  to  the  use  of  tranexamic  acid
in  patients  undergoing  medium  to  major  orthopedic  proce-
dures.  This  increase  is  based  on  the  effects  of  antiﬁbrinolytic
drugs  associated  with  prolonged  bed  rest  and  prothrombotic
activity  of  the  inﬂammatory  response  to  surgical  trauma.
However,  in  the  present  study,  in  which  the  drug  prophy-
laxis  was  used  (subcutaneous  unfractionated  heparin  5000  IU
every  8 h)  associated  with  use  of  compression  stockings  for
1257
even  days  perioperatively,  there  was  no  evidence  of  throm-
oembolic  events  in  both  groups  of  patients.
A  study  assessing  the  efﬁcacy  and  safety  of  increasing
oses  of  intravenous  tranexamic  acid  (1000  mg;  2000  mg;
nd  3000  mg)  in  patients  undergoing  total  knee  replacement
howed  no  thromboembolic  events  in  studied  groups.24
Several  studies  have  failed  to  show  an  association
etween  the  use  of  tranexamic  acid  and  the  occurrence  of
hromboembolic  events.9,13 The  likely  explanation  for  these
ndings  lies  in  the  fact  tranexamic  acid  does  not  affect  ﬁb-
inolytic  activity  on  the  walls  of  the  veins  and  promote  no
rothrombotic  activity  in  the  studied  groups.13
In  this  study,  we  conclude  that  the  use  of  tranexamic
cid  reduces  postoperative  bleeding  in  primary  total  knee
eplacement,  with  the  absence  of  thromboembolic  events.
owever,  additional  studies  are  needed  to  assess  its  impact
n  the  need  for  transfusion  of  blood  and  blood  products.
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